Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
Titel:
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
Auteur:
Robertson, John F. R. Lindemann, Justin P. O. Llombart-Cussac, Antonio Rolski, Janusz Feltl, David Dewar, John Emerson, Laura Dean, Andrew Ellis, Matthew J.